The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial
- PMID: 31371212
- DOI: 10.1016/S2215-0366(19)30215-9
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial
Abstract
Background: Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear. We aimed to examine whether combined treatment with CBT and fluoxetine was more effective than CBT and placebo in youth with moderate-to-severe major depressive disorder.
Methods: The Youth Depression Alleviation-Combined Treatment (YoDA-C) trial was a randomised, double-blind, placebo-controlled, multicentre clinical trial. Participants were aged 15-25 years with moderate-to-severe MDD and had sought care at one of four clinical centres in metropolitan Melbourne, Australia. Patients were randomly assigned (1:1) to receive CBT for 12 weeks, plus either fluoxetine or placebo. Participants began on one 20 mg capsule of fluoxetine or one placebo pill per day. All participants received CBT, delivered by therapists in weekly 50-minute sessions and attended interviews at baseline, and at weeks 4, 8, and 12, during which they completed assessments with research assistants. Participants saw a psychiatrist or psychiatry trainee to complete medical assessments at the same timepoints. The primary outcome was change in the interviewer-rated Montgomery-Åsberg Depression Rating Scale (MADRS) score at 12 weeks. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12612001281886).
Findings: 153 participants (mean age 19·6 years [SD 2·7]) were enrolled from Feb 20, 2013, to Dec 13, 2016. 77 (50%) patients were allocated to CBT and placebo and 76 (50%) to CBT and fluoxetine. Participants had severe depression at baseline (mean MADRS score 33·6 [SD 5·1] in the CBT and placebo group and 32·2 [5·6] in the CBT and fluoxetine group), with high proportions of participants with anxiety disorder comorbidity (47 [61%] in the CBT and placebo group and 49 [64%] in the CBT and fluoxetine group) and past-month suicidal ideation (55 [71%] in the CBT and placebo group and 59 [78%] in the CBT and fluoxetine group). 59 (77%) participants in the CBT and placebo group and 64 (84%) in the CBT and fluoxetine group completed follow-up at week 12. After 12 weeks of treatment both groups showed a reduction in MADRS scores (-13·7, 95% CI -16·0 to -11·4, in the CBT and placebo group and -15·1, -17·4 to -12·9, in the CBT and fluoxetine group). There was no significant between-group difference in MADRS scores (-1·4, -4·7 to 1·8; p=0·39). There were five suicide attempts in the CBT and placebo group and one suicide attempt in the CBT and fluoxetine group (odds ratio 0·2, 0·0-1·8; p=0·21), and no significant between-group differences for other suicidal behaviours.
Interpretation: We did not find evidence that the addition of fluoxetine (rather than placebo) to CBT further reduced depressive symptoms in young people with moderate-to-severe MDD. Exploratory analyses showed that the addition of medication might be helpful for patients with comorbid anxiety symptoms and for older youth.
Funding: Australian National Health and Medical Research Council.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
-
Youth depression: are two treatments better than one?Lancet Psychiatry. 2019 Sep;6(9):714-715. doi: 10.1016/S2215-0366(19)30281-0. Epub 2019 Jul 29. Lancet Psychiatry. 2019. PMID: 31371211 No abstract available.
Similar articles
-
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.Trials. 2014 Nov 4;15:425. doi: 10.1186/1745-6215-15-425. Trials. 2014. PMID: 25370185 Free PMC article. Clinical Trial.
-
A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.Health Technol Assess. 2008 May;12(14):iii-iv, ix-60. doi: 10.3310/hta12140. Health Technol Assess. 2008. PMID: 18462573 Clinical Trial.
-
Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people.Aust N Z J Psychiatry. 2021 May;55(5):506-516. doi: 10.1177/0004867421998763. Epub 2021 Mar 15. Aust N Z J Psychiatry. 2021. PMID: 33722073 Clinical Trial.
-
Venlafaxine extended-release: a review of its use in the management of major depression.CNS Drugs. 2001;15(8):643-69. doi: 10.2165/00023210-200115080-00007. CNS Drugs. 2001. PMID: 11524036 Review.
-
Clinical messages from the Treatment for Adolescents With Depression Study (TADS).Am J Psychiatry. 2009 Oct;166(10):1118-23. doi: 10.1176/appi.ajp.2009.08101606. Epub 2009 Sep 1. Am J Psychiatry. 2009. PMID: 19723786 Review.
Cited by
-
Effect of Acceptance and Commitment Therapy on Emotion Regulation in Adolescent Patients with Nonsuicidal Self-Injury.Alpha Psychiatry. 2024 Jan 1;25(1):47-53. doi: 10.5152/alphapsychiatry.2024.231324. eCollection 2024 Jan. Alpha Psychiatry. 2024. PMID: 38799501 Free PMC article.
-
Music prevents stress-induced depression and anxiety-like behavior in mice.Transl Psychiatry. 2023 Oct 12;13(1):317. doi: 10.1038/s41398-023-02606-z. Transl Psychiatry. 2023. PMID: 37828015 Free PMC article.
-
Abnormal brain activity in lumbar disc herniation patients with chronic pain is associated with their clinical symptoms.Front Neurosci. 2023 Jul 28;17:1206604. doi: 10.3389/fnins.2023.1206604. eCollection 2023. Front Neurosci. 2023. PMID: 37575297 Free PMC article.
-
Possible Involvement of Perineuronal Nets in Anti-Depressant Effects of Electroacupuncture in Chronic-Stress-Induced Depression in Rats.Neurochem Res. 2023 Oct;48(10):3146-3159. doi: 10.1007/s11064-023-03970-4. Epub 2023 Jun 22. Neurochem Res. 2023. PMID: 37347359
-
Latest updates on the serotonergic system in depression and anxiety.Front Synaptic Neurosci. 2023 May 9;15:1124112. doi: 10.3389/fnsyn.2023.1124112. eCollection 2023. Front Synaptic Neurosci. 2023. PMID: 37228487 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous